The researchers highlighted that psoriasis is a systemic condition linked to various comorbidities, emphasizing the ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s (NYSE JNJ) Tremfya (guselkumab), the ...

Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...

In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended remissions and protection against PsA relative to other biologics.

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis, ...

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in ...

Five-year data from Phase III trials demonstrated that 67.7% of patients moderate-to-severe plaque psoriasis treated with UCB ...

Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to ...